Postexposure Prophylaxis for Hepatitis A
Prevent the threat with GamaSTAN® (immune globulin [human]) postexposure prophylaxis for hepatitis A.
Hepatitis A is primarily spread when an uninfected and unvaccinated person ingests food or water that is contaminated with the feces of an infected person. This can happen a number of ways, such as if those handling the food at a restaurant haven't properly washed their hands, or by drinking or eating contaminated food, water, and ice in areas with poor sanitation, which is why travelers to developing countries should be careful. Sexual contact with an infected person and intravenous use can increase risk of infection as well.1
According to the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), when administered within 2 weeks after exposure to the hepatitis A virus, an intramuscular immune globulin, such as GamaSTAN, is 80% to 90% effective in preventing hepatitis A.2
For more information concerning the CDC ACIP recommendations and guidelines, visit the CDC ACIP website.
GamaSTAN is a sterile solution of immune globulin for intramuscular administration for postexposure prophylaxis for hepatitis A, providing rapid immune protection for up to 3 months.3,4
Safety Is a Priority3
- GamaSTAN is mercury (thimerosal) free and latex free
- GamaSTAN has Food and Drug Administration (FDA) labeling for capacity to remove pathogenic prions that may cause transmissible spongiform encephalopathies in humans
- Studies of the GamaSTAN manufacturing process demonstrated that TSE clearance is achieved during the Pooled Plasma to Effluent III Fraction Process (6.7 log10). These studies provide reasonable assurance that low levels of Creutzfeldt-Jakob disease (CJD) or variant CJD agent infectivity, if present in the starting material, would be removed
- GamaSTAN provides tamper-evident packaging
- GAMASTAN is made from human blood; it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent